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DObjective: We examined outcomes after mitral valve replacement in children younger than 8 years.
Methods: Medical records of patients who underwent mitral valve replacement from 1990 to 2006 were re-
viewed. Competing-risks methodology determined time-related prevalence and associated factors for death, re-
peated valve replacement, and survival without reoperation.
Results: In total, 79 patients, median age 24 months (40 days–8 years) underwent 91 mitral valve replacements
(10 had repeated procedures). Underlying pathology was congenital heart disease in 95% of cases. Forty-six pa-
tients (58%) had undergone previous operations. Operative mortality was 18%, 30% for those 2-years old and
younger and 6% for those older than 2 years. Competing-risks analysis showed that 10 years after initial mitral
valve replacement, 40% of patients had died without repeated replacement, 20% had undergone a second re-
placement, and 40% remained alive without further replacement. Factors associated with death included higher
prosthesis size/patient weight ratio (P< .0001) and longer crossclamp time (P< .0001). Second replacement
6  4 years after initial replacement was necessary for 10 survivors. At second replacement, larger prostheses
were implanted (mean 24 mm vs 19 mm initially). Repeated MVR was associated with younger age at surgery
(p ¼ .006). Permanent pacemaker implantation was eventually needed by 11% of hospital survivors.
Conclusions:Mortality and repeated valve replacement are common after mitral valve replacement in children
younger than 8 years, especially younger patients with significantly oversized valves. At valve reoperation,
larger prostheses could be implanted, suggesting continued annular growth. (J Thorac Cardiovasc Surg
2010;139:1189-96)Supplemental material is available online.
Valve repair is the treatment of choice in mitral valve and
systemic atrioventricular valve dysfunction1; however, mitral
valve replacement (MVR) may still be required by a subset
of children for whom the mitral valve cannot be repaired.
MVR in pediatric patients is associated with distinct clinical
and technical problems.2-11 MVR is especially challenging in
young children because the small sizes of the native valve
annulus, atrium, and ventricle predispose them toward com-
plications related to leaflet entrapment, development of left
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The Journal of Thoracic and Carobstruction, and conduction block. In addition to significant
morbidity, replacement in this age group has a high operative
mortality, ranging from 10% to 36%.2-14 Moreover, MVR
in small children is associated with increased late morbidity
and long-term anticoagulation, the need for subsequent pros-
thetic valve replacement as the child outgrows the initial
valve, and the deterioration of ventricular function from
the development of patient-prosthesis size mismatch.2-14
Our aim in this study was to examine factors associated
with the mutually exclusive time-related events of death
and repeated replacement in young children (<8 years)
who underwent MVR at our institution.MATERIALS AND METHODS
Inclusion Criteria
From 1990 to June 2006, a total of 79 consecutive children younger than
8 years required MVR at the King Faisal Heart Institute in Riyadh, Saudi
Arabia. Patients were identified from the hospital surgical database. Clini-
cal, operative, and outcome data were abstracted from the medical records.
Approval of this study was obtained from the research ethics board at our
institution, and requirement for individual consent was waived for this ob-
servational study.
Patient Characteristics
During the study period, 79 patients (37 of them male) underwent an ini-
tial MVR. Median age at index operation was 24 months (range, 40 days–8diovascular Surgery c Volume 139, Number 5 1189
Abbreviations and Acronyms
AVSD ¼ atrioventricular septal defect
MVR ¼ mitral valve replacement
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Dyears), and median weight was 9 kg (range, 3–23 kg). Age distribution at
time of initial MVR is shown in Figure E1. The underlying valve disease
was congenital mitral valve disease in 73 patients, Marfan syndrome in 2
patients, rheumatic disease in 1 patient, endocarditis in 1 patient, and sec-
ondary to other cardiac surgery (Ross procedure and subaortic membrane
resection) in 2 patients. Congenital heart disease included isolated mitral
valve anomaly in 34 patients, atrioventricular septal defect (AVSD) in 22
patients, atrioventricular discordance (congenitally corrected transposition
of the great arteries) with Ebstein malformation in 12 patients, multiple
left-sided obstructive lesions (Shone complex) in 4 patients, and other car-
diac lesions in 5 patients.
Before MVR, procedures to address mitral valve lesions or other cardiac
lesions were performed in 46 patients (58%). Other than correction of the
AVSD, 20 patients had undergone previous operative attempts at mitral
valve repair. The hemodynamic mitral dysfunction was primarily regurgita-
tion in 60 patients (76%), stenosis in 11 patients (14%), and mixed in 8 pa-
tients (10%). Of the entire cohort, 69 patients had only 1 MVR, 8 patients
had 2 MVRs, and 2 patients had 3 MVRs, for a total of 91 operations. Pa-
tients’ demographic and operative characteristics at initial MVR are listed in
Table E1.Operative Details
All procedures were performed though midline sternotomy. Cardiopul-
monary bypass was established by standard aortic and bicaval venous can-
nulation. The left ventricle was decompressed by venting through the right
superior pulmonary vein. Moderate hypothermia (28C–30C) was used.
Myocardial protection was provided with cold blood cardioplegia. In very
small infants, deep hypothermic circulatory arrest was occasionally used
briefly to improve exposure.
The mitral valve was approached directly by way of the left atrium
through the interatrial groove. In certain cases, such as early after AVSD re-
pair or in patients with small left atrium, a transseptal approach was used.
Once the decision had been made to replace the mitral valve, the aim was
to preserve the posterior mitral leaflet with supporting chordal apparatus.
Inmost patients (71%), however, this was not possible because of severe de-
formity of the subvalvular structure or small space that did not allow insertion
of an adequately sized prosthesis. The prosthesiswas placedwithin themitral
annulus in all patients. Occasionally, the prosthesis was tilted at the posterior
annular level with sutures placed in the left atrium rather than the annulus to
permit placement of the large prosthesis (n¼ 17, 22%). None of the patients
had complete supra-annular placement of the mitral prosthesis.
All patients received mechanical valves. Most valves (n¼ 76) were Car-
boMedics valves (Sorin SpA, Milan, Italy), in addition to St Jude (St Jude
Medical, Inc, St Paul, Minn), On-X (On-X Life Technologies, Inc, Austin,
Tex), and ATS (ATSMedical, Inc, Minneapolis, Minn) valves (n¼ 1 each).
The median valve size was 21 mm (range 16–27 mm).
After completion of the MVR, patients underwent intraoperative transe-
sophageal echocardiography to assess prosthetic function. Concomitant car-
diac surgical procedures were carried out in 14 cases. Those included
tricuspid valve repair (n ¼ 5), closure of ventricular septal defect (n ¼ 5),
debanding (n ¼ 2), relief of left ventricular outflow tract obstruction
(n ¼ 2), resection of ascending aortic aneurysm (n ¼ 1), aortic valve repair
(n¼ 1), right ventricle–pulmonary artery conduit change and pulmonary an-
gioplasty (n¼ 1), and closure of multiple ventricular septal defects (n¼ 1).
Mean duration of cardiopulmonary bypass and aortic crossclamp time were
127  70 and 79  33 minutes, respectively.1190 The Journal of Thoracic and Cardiovascular SurAnticoagulation Protocol
After the operation, once adequate hemostasis had been obtained, all pa-
tients were given heparin intravenously to maintain the partial thromboplas-
tin time ratio between 1.5 and 2 times baseline. In addition, all patients
received oral warfarin sodium (INNwarfarin) aimed at maintaining an inter-
national normalized ratio within the range of 2.5 to 3.5. Patients were seen
regularly by the pediatric cardiologists, on average 1 visit yearly, and anti-
coagulation was followed up by specialized local anticoagulation clinics
with established anticoagulation protocols. Antiplatelet medications were
not routinely prescribed, however, they were given occasionally to a few pa-
tients in whom international normalized ratio control was difficult.
Follow-up
Late outcomes were determined from recent office visits at King Faisal
Specialist Hospital and Research Center or from direct correspondence
with patients’ families. The mean follow-up duration was 4.1  3.7 years
(up to 14.7 years). Five patients had moved abroad and could not be located,
making follow-up 94% complete.
Statistical Analysis
Data are presented as mean  SD, median with range, and frequency as
appropriate. Time-dependent outcomes (death and reoperation) after MVR
were parametrically modeled. Parametric probability estimates for time-de-
pendent outcomes usedmodels based onmultiple overlapping phases of risk
(available for use with the SAS statistical software system [SAS Institute,
Inc, Cary, NC] at http://www.clevelandclinic.org/heartcenter/hazard). The
HAZARD procedure uses maximum likelihood estimates to resolve risk
distribution of time to event in up to 3 phases of risk (early, constant, and
late). Competing-risks analysis was performed to model the probability
with time of each of 2 mutually exclusive end points, reoperative MVR
and death without second MVR, with the remainder of patients being
both alive and free from second MVR. Variables potentially influencing
the likelihood of outcomes in the competing-risks models were sought
from demographic, anatomic, and surgical variables through a bootstrap
bagging algorithm (500 samples). Potential risk factors also included
multiple mathematic transformations of continuous variables (log,
squared, square root, exponential, inverse) and interaction criteria
between age at surgery and prosthesis size. Variables appearing in at least
50% of samples were retained in the final model, which used stepwise
regression algorithm (P< .05 to enter) to obtain the final model for each
phase of risk (Appendix E1). Effects of covariates on the probabilities of
outcomes in competing-risks models are given as parameter estimates
with percentage reliabilities in the bootstrap algorithm. Clinical relevance
of identified covariates to likelihoods of selected outcomes was
established by solving the regression equations for multiple ‘‘typical’’ test
patients. All statistical analyses were performed with SAS statistical
software v9.1.RESULTS
Operative Mortality and Morbidity
A total of 14 (18%) patients died within the first 30 days
after the operation or before hospital discharge. Most deaths
occurred in the immediate postoperative period andwere car-
diac related (low cardiac output syndrome in 9, pulmonary
hypertension in 2, left ventricular outflow tract obstruction
in 1, tricuspid valve obstruction in 1, myocardial infarction
after left circumflex arterial injury in 1). Complications con-
tributing to death included postoperative hemorrhage in 2
and sepsis and multiorgan failure in 2. Extracorporeal mem-
brane oxygenation support was necessary for 2 patients,gery c May 2010
FIGURE 1. A, Model for survival to reoperation has only late phase, be-
cause risk of reoperation steadily increases as years since surgery progress.
Solid lines represent parametric point estimates, dashed lines enclose 70%
confidence intervals, and circles with error bars represent nonparametric
estimates. B, Hazard function for mitral valve reoperation.
FIGURE 2. A, Model for raw survival is composed of 2 phases of risk,
early phase with high level of risk in immediate postoperative period and
a constant phase indicating low attrition rate with time. Solid lines represent
parametric point estimates, dashed lines enclose 70% confidence intervals,
and circles with error bars represent nonparametric estimates. B, Hazard
function for death.
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heart block necessitating permanent pacemaker implantation
was seen in 7 patients (11% of survivors).
Competing-Risks Analysis for Death or Subsequent
Prosthesis Replacement After Initial MVR
After the 79 initial MVRs, 10 patients had their prosthetic
valves subsequently replaced and 24 patients died without
further MVR. The hazard function for time-related transition
to a second MVR was characterized by the absence of an
early phase of risk and by a prolonged late hazard phase,
with reoperation rate steadily increasing as years since sur-
gery progressed (Figure 1). The hazard function for time-re-
lated transition to death without a second MVR was
characterized by an early hazard phase with a high level of
risk in the immediate postoperative period and a constant
hazard phase indicating a low risk of attrition with time
(Figure 2).The Journal of Thoracic and CarThe competing-risks analysis for the 2 events showed that
at 6 months after surgery nearly 20% of patients would be
expected to have died. Thereafter, the risks of death and re-
operation remained constant to 5 years after surgery (affect-
ing a further 10% of patients each during this period). After
5 years, the risk of death remained low, but the risk of reop-
eration increased. At 10 years after initial MVR, approxi-
mately 40% of patients had died, 20% had undergone
reoperativeMVR, and 40% remained alive and free from re-
operation (Figure 3).
Factors associated with early-phase and constant-phase
risks of death and with late-phase risk of subsequent reoper-
ativeMVRafter initialMVRwere sought. Significant factors
for early-phase mortality were higher ratio of prosthesis size
to patient weight (parameter estimate 0.78  1.19,
P<.0001) and longer aortic crossclamp time (parameter es-
timate 0.58  1.13, P< .0001). Younger age at MVR was
a significant factor for late-phase reoperation risk (parameter
estimate 1.19  0.30, log transformed, P ¼ .006; Table 1).diovascular Surgery c Volume 139, Number 5 1191
FIGURE 3. Competing-risks analysis depiction of events after initial
mitral valve replacement in 79 children younger than 8 years. After initial
mitral valve replacement, patients could transition to either death or a subse-
quent replacement. At any point, sum of percentages of children in each
state is 100%. At 10 years after initial surgery, approximately 40% of pa-
tients have died, 20% have undergonemitral reoperation, and 40% are alive
and free from reoperation.
FIGURE 4. Stratified analysis of risk of death by ratio of implanted valve
size (VS) to patient weight (W). Unfavorable effect on mortality of higher
ratio is shown.
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size was explored as a potential risk factor. Although the in-
teraction was significant as an early-phase risk factor for
mortality, the model fit was better (by log likelihood criteria)
when expressed as a ratio of prosthesis size to patient weight.
The higher risk of death associated with larger ratio of im-
planted prosthesis size to patient weight ratio is shown in
Figure 4. The increased risk of reoperation associated with
younger age at initial MVR is depicted in Figure 5.Outcomes of Second MVR
Overall, 10 survivors underwent second MVR, on aver-
age 6.4 3.9 years after the initial MVR. At the time of sec-
ond MVR, larger prosthesis were implanted (mean, 24 mm
vs 19 mm initially). Within the study follow-up period, 2
of the patients who had undergone a second MVR requiredTABLE 1. Factors associatedwith time-related death or secondmitral
valve replacement
Parameter
estimate ± SE
P
value
Reliability
(%)
Factors affecting risk of death
Early phase
Higher prosthetic size/patient
weight
0.771  1.189 <.0001 52%
Longer crossclamp time
(per 10 min)
0.582  0.127 <.0001 62%
Constant phase
No factors identified
Factors affecting risk of subsequent valve reoperation
Late phase
Younger age at surgery (log y) 1.192  0.299 .006 80%
1192 The Journal of Thoracic and Cardiovascular Sura thirdMVR, both urgently, for valve thrombosis and a stuck
leaflet related to a pannus. After second and third MVRs,
there were no deaths, no endocarditis, and no further throm-
botic complications beyond those previously described.
Complications
Overall survivals were 85% at 1 month, 80% at 1 year,
73% at 5 years, and 62% at 10 years (Figure 6). Valve-re-
lated complications were infrequent; however, major hemor-
rhagic episodes occurred in 5 patients (intracranial bleeding
in 4, gastrointestinal bleeding in 1). Three of those hemor-
rhagic events were trauma related as the result of a fall,
and bleeding was the cause of late death in 2 of those cases.
In addition, there were 4 documented valve thromboses (ex-
cluding sudden cardiac death episodes); 3 patients survived
the subsequent required reoperative MVR and 1 died before
reoperation. Freedom from valve thrombosis at 10 years was
90%. None of the patients in our series had a documented
embolic event or a hospital admission for endocarditis.
Overall freedoms from valve-related complications (exclud-
ing reoperation or death) were 98% at 1 year, 83% at
5 years, and 80% at 10 years.gery c May 2010
FIGURE 5. Stratified analysis of risk of reoperation by age at initial sur-
gery. Unfavorable effect on mitral reoperation of age is shown.
FIGURE 7. Graph showing relationship between ratio of prosthesis size to
weight and age.
FIGURE 6. Overall freedom from all-cause time-related mortality after
mitral valve replacement in children younger than 8 years.
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DDISCUSSION
Our study reports a single institution’s experience with
MVR in 79 children younger than 8 years. Competing-risks
analysis was chosen because these patients were at risk
simultaneously for 2 mutually exclusive events, death and
reoperation with prosthesis replacement. Conventional
time-related analyses consider individual events such as
death or reoperation either in isolation or as a combined
end point. Although useful, such analyses do not address
the question of how often an event may occur in the absence
of other events for which a patient is at simultaneous risk.
Mortality
Early mortality was 18% in this study, comparable to
other reports in which early mortality after initial MVR
has ranged between 11% and 36%.2-14 The reported early
mortality after MVR during the first 2 years of life is even
higher (as high as 52%). Similarly, in our series, operative
mortality in children younger than 2 years was 30%, com-
pared with 6% in children 2 to 8 years old.2-14
We identified increased ratio of prosthetic valve size to
patient’s weight as a significant risk factor for early-phaseThe Journal of Thoracic and Carmortality. Most of our patients received prostheses that
were relatively larger than the annular size, and in some
cases the ratio of prosthesis size to patient’s weight was as
high as 6.3 (Figure 7). Those patients represent mostly small
children with low body weight for whom selection of an
oversized prosthesis was inevitable because of the lack of
availability of smaller prostheses. Surgeons also may at-
tempt to oversize the prosthesis deliberately in an effort to
increase its longevity. Our data suggest that such a strategy
of valve oversizing is not advisable. The small sizes of the
valve annulus, left atrium, and left ventricle in relation to
available prostheses may produce significant geometric dis-
parity, with subsequent potential for leaflet entrapment, left
ventricular outflow tract obstruction, tricuspid valve ob-
struction, circumflex artery injury, and conduction block,
all of which may be associated with increased operative
risk.2-14 All those complications were observed in our series
and were associated with significant operative mortality. Re-
cently, after this series and not included in the current patient
cohort, 2 infants at our institution showed additionaldiovascular Surgery c Volume 139, Number 5 1193
Congenital Heart Disease Alsoufi et al
C
H
Dcomplications leading to operative mortality: 1 had addi-
tional tricuspid valve obstruction, and 1 had rupture of the
posterior wall of the left ventricle in the intensive care unit
within 24 hours after MVR. Eleven patients in our series
did not survive MVR because of persistent severe low car-
diac output state or pulmonary hypertension. Unidentified
obstructions of adjacent cardiac structures, including the
pulmonary veins, may have also been unrecognized major
contributing factors to operative mortality. Although most
patients with larger discrepancy between the prosthesis
and body weight were very young (Figure 7), this associa-
tion between early-phase survival and ratio of valve size to
patient weight was seen in both younger and older children,
as demonstrated in Figure E2.
Other reports have similarly identified larger ratio of pros-
thesis size to patient weight as a significant risk for mortal-
ity.8,10,14 Caldarone and associates8 noted that geometric
disparity according to calculations of ratio of prosthetic valve
size to patient body weight affected operative mortality and
suggested that other surgical options be considered if themitral
valve couldn’t be repaired in those very young patients. Those
surgical alternatives might include abandonment of the left
ventricle with atrial septectomy and a Damus–Kaye–Stansel
anastomosis or heart transplantation. Those options should
be carefully considered on the basis of individual patient anat-
omy, presence of pulmonary hypertension, hospital resources,
and individual institutional outcomes.
Ratio of prosthesis size to patient weight mirrored the re-
lationship between the prosthesis and predicted mitral annu-
lar diameter. Nonetheless, in a heterogeneous group of
children requiring MVR for various cardiac malformations,
the actual sizes of the mitral annulus and adjacent cardiac
structures vary.11 In children with Marfan, idiopathic dilated
cardiomyopathy, or other pathologies such as ischemic car-
diomyopathy secondary to congenital coronary artery anom-
alies, the mitral annular diameter may be very large, whereas
in those with mitral stenosis from Shone complex, hypopla-
sia of the mitral annulus and adjacent left heart structures
may exist. Some authors have therefore suggested that the
use of the z score difference between the prosthesis size
and measured annular size is a more suitable parameter to
analyze prosthesis–patient mismatch than the ratio of pros-
thesis size to body weight.11,14 Eble and colleagues14 mea-
sured the difference between the z score of the implanted
prosthesis and the z score of the measured mitral annulus.
They defined oversizing as a z score difference greater
than 1 and undersizing as a difference under1. They found
that increased z score difference was an independent risk fac-
tor for poor outcome.14 Ackermann and associates11 found
that the ratio of prosthesis size to body weight was a signifi-
cant factor for mortality; when comparing z score differences
between the prosthesis and measured annular sizes, how-
ever, there was no significant effect of size disparity on sur-
vival or reoperation.1194 The Journal of Thoracic and Cardiovascular SurSimilar to Caldarone, we chose to use ratio of prosthesis
size to body weight as a marker of prosthesis oversizing be-
cause of its simplicity, the ease with which it can be calcu-
lated and the strong association with increased early-phase
mortality after MVR.8,10 Our results should be interpreted
in light of our study limitations. Although the 2 indicators
are parallel in most cases, the absolute size of the prosthesis
relative to the patient weight may be less important than the
size relative to the available annulus. Patients with small an-
nulus and cardiac structures are probably at higher risk for
complications related to geometric disparity between the
prosthesis and the heart. Our series does not include many
patients for whom the measured and predicted annular sizes
diverged significantly, and the ratio of prosthesis size to
weight therefore seems to be a good representative of pros-
thesis-patient mismatch.
Additional risk factors that have been identified in previ-
ous reports include complete atrioventricular septal defect,
Shone complex, diagnosis other than congenital heart dis-
ease, and increased cardiopulmonary bypass duration.2-14
Longer aortic crossclamp time was also identified as a risk
factor for early-phase mortality in our study. This may re-
flect the complexity of the disease, with adverse effects on
cardiac perfusion and other organs due to long cardiac is-
chemic duration and prolonged exposure to cardiopulmo-
nary bypass.
Reoperative MVR
We found 1 factor to be associated with higher risk for re-
peated valve replacement after the initial MVR, and that was
younger age at initial surgery. This factor may be a proxy for
the fact that patients who require MVR at a younger age usu-
ally receive smaller mitral valve prostheses. Although those
prostheses are considered too big relative to the left heart
structures at time of implantation, as the patient grows,
this ratio of prosthesis to patient size reverses and the pros-
thesis becomes too small and stenotic, causing worsening
symptoms and deteriorating cardiac function thus necessitat-
ing earlier reoperative MVR.
Moreover, in addition to the effect of the relatively large
prosthesis on adjacent cardiac structures, which contributes
to early morbidity and mortality as discussed previously,
this relatively large prosthesis is subject to leaflet entrap-
ment and generation of inflammatory or immunologic re-
sponse, which may increase the risk of fibrosis and
pannus formation, with possible complications such as
valve obstruction or thrombosis requiring early reopera-
tion.
Young age and the need to implant a small prosthesis are
unfortunately not modifiable factors, and the only option
available to the surgeon is to attempt mitral valve repair
in this subgroup of young patients as a temporizing mea-
sure until the child has grown older and is able to receive
a larger prosthesis. Our data suggest that placement of angery c May 2010
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able to valve oversizing, although at the probable expense
of earlier reoperation requirement. This suggestion is based
on three findings. First, significant discrepancy between the
prosthesis size and patient weight was found to be a signif-
icant risk factor for early mortality. Second, reoperative
MVR was not associated with increased operative mortal-
ity but rather was associated with lower mortality than
that of initial MVR in our experience, as well as in other
published reports.8-10,15 Finally, after a mean interval of
6.4 years between initial MVR and reoperation (shorter
for those who underwent MVR at a younger age), the sur-
geon was able to place a mitral prosthesis that was on av-
erage 5 mm larger than the explanted prosthesis. This
finding suggests that the annulus continues to grow after
MVR in young children despite the fixed size of the small
prosthesis sewing ring.9Late Complications
Late valve-related morbidity in our series was limited
mainly to bleeding and valve thrombosis. The 10-year free-
doms from each of those 2 complications were 90%. Al-
though the risk of anticoagulation-related hemorrhage is
not higher than that in adults, the risk of valve thrombosis
seems to be higher.16 In addition to problems with antico-
agulation, local factors such as the relatively large prosthe-
sis size compared with the left heart structures may
predispose the patient toward pannus formation and leaflet
entrapment and increase the risk of subsequent valve
thrombosis. The risk of embolic events relative to that in
adults was minimal in our experience and in other series
as well.2-14
Nonetheless, we should not forget that there has been
a steady attrition rate in this young population, with many
sudden deaths that are most likely the result of undetected
valve-related complications. Moreover, many of our bleed-
ing events were trauma related, with 2 patients dying of
trauma-related hemorrhage. This fact highlights the delicate
problem of compliance with an anticoagulation regimen,
with its implication for patient lifestyle, which is especially
difficult to control in young children.Study Limitations
This report represents a retrospective analysis of patients
from a single institution with diverse anatomy who under-
went MVR during a 16-year period. It is subject to all in-
herent deficiencies associated with any retrospective
review. Undoubtedly, indications for valve replacement,
timing of operation, and operative technique were not con-
stant with time. In addition, prosthesis selection and oper-
ative procedures were neither standardized nor
randomized. Finally, although a comprehensive set of vari-
ables was used in all analyses, unmeasured covariates mayThe Journal of Thoracic and Carhave contributed to disparate outcomes in the recipient
populations.SUMMARY
The outcome afterMVR in children younger than 8 years is
associated with a high risk of early death, followed by a late
phase of risk associated with low attrition rate despite long-
term anticoagulation and the need for subsequent MVR.
Discrepancy between prosthesis size and body weight was
common in these patients and was associated with higher
risk of negative outcomes, with larger discrepancies (greater
ratio of prosthetic valve size to body weight) being associated
with higher early mortality. Valve oversizing is therefore not
recommended, and appropriately sized prostheses should be
used to avoid significant geometric disparity with the patient’s
heart and thus prevent related complications. Normalization
of growth in survivors changes the ratio of prosthesis size
to body weight with time, and eventually the prosthesis be-
comes obstructive, thus necessitating earlier reoperative
MVR. At of reoperation, larger valve prostheses could be im-
planted, suggesting continuous annular growth despite fixed
prosthesis size. Valve replacement at that time is associated
with diminished mortality and increased valve longevity rel-
ative to values in younger children.References
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Appendix E1. Variables Used in Multivariable Analyses
Demographic
Age, weight, body surface area
Mitral valve pathology
Hemodynamic manifestation (stenosis, regurgitation, mixed), underlying pathology (congenital, endocarditis, rheumatic,
connective tissue disease), specific congenital disorders (atrioventricular septal defect, Shone, atrioventricular discordance),
previous cardiac surgery
Details of mitral valve surgery
Prosthesis type, prosthesis size (external diameter size), ratio of prosthesis size to patient weight, ratio of prosthesis size to
body surface area, additional cardiac surgery, cardiopulmonary bypass duration, aortic crossclamp duration
Experience
Date of operation
FIGURE E1. Age distribution of patients at initial mitral valve replace-
ment.
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TABLE E1. Demographic and operative variables at initial mitral
valve replacement
Demographic characteristics
No. of patients 79
Study dates 1990–2006
Sex (No. male) 37 (47%)
Age at surgery (y)
Mean  SD 2.8  2.3
Median (range) 2.2 (0.1–8.0)
Weight at surgery (kg)
Mean  SD 9.8  4.5
Median (range) 9.4 (3.0–22.8)
Body surface area at surgery (m2)
Mean  SD 0.47  0.16
Median (range) 0.46 (0.23–0.82)
Medical history
Pathology (No.)
Regurgitation 60/79 (76%)
Stenosis 11/79 (14%)
Both 8/79 (10%)
Underlying congenital anomaly (No.)
Isolated mitral 34/79 (43%)
Atrioventricular septal defect 22/79 (28%)
Atrioventricular discordance* 12/79 (15%)
Shone complex 4/79 (5%)
Other 7/79 (9%)
Previous operations (No.)
0 33/79 (42%)
1 35/79 (44%)
2 11/79 (14%)
Surgical variables
Prosthesis size (external diameter, mm)
Mean  SD 21  3
Median (range) 21 (16–27)
Valve size/patient weight at surgery (mm/kg)
Mean  SD 2.6  1.1
Median (range) 2.3 (1.0–6.3)
Duration of cardiopulmonary bypass (min)
Mean  SD 127  70
Median (range) 107 (55–432)
Duration of aortic crossclamp (min)
Mean  SD 79  33
Median (range) 69 (33–182)
Postsurgical outcome
10-y freedoms (%)
Repeated mitral valve replacement 71% (50%–92%)
All-cause mortality (survival) 62% (46%–78%)
Thrombosis 90% (80%–100%)
Embolism 100% (100%–100%)
Bleeding events 83% (72%–95%)
Endocarditis 100% (100%–100%)
Duration of follow-up (y)
Mean  SD 4.1  3.7
Median (range) 3.3 (0.0–14.7)
Duration of follow-up after reoperation (y)
Mean  SD 4.2  4.3
Median (range) 1.9 (0.7–13.0)
*Congenitally corrected transposition of great arteries.
FIGURE E2. A, Stratified analysis of risk of death by ratio of implanted
valve size (VS) to weight (W) in children younger than 2 years. Unfavorable
effect on mortality of ratio is shown. B, Stratified analysis of risk of death by
ratio of valve size to weight in children between 2 and 8 years old. Unfavor-
able effect on mortality of ratio is shown. Graphs clearly show that although
risk of death is higher in younger patients than in older ones, ratio of valve
size to weight is risk factor for mortality in both groups.
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